A Phase II Study of 9-ING-41 GSK-3? Combined with Retifanlimab plus Gemcitabine/Nab-Paclitaxel as Frontline Therapy for Patients with Advanced Pancreatic Adenocarcinoma

Brief Summary

Type:
Pancreatic

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT05239182

Study #:
STUDY00147908

Start Date:
Feb 16, 2022

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05239182

View Complete Trial Details & Eligibility at ClinicalTrials.gov